[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562464":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":24,"overallOfficials":13,"centralContacts":29,"locations":39,"responsibleParty":55,"collaborators":13,"id":57,"slug":13,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":13,"enrollmentInfo":65,"targetDuration":13,"studyType":68,"phases":13,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":42,"whyStopped":13,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Centre Francois Baclesse","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of establishment of exploitable tumor organoid lines","Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.","through study completion, an average of 3 years",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","Patient with localized endometrial cancer",[19],{"label":20,"type":13,"description":21,"interventionNames":22},"tumour and blood collection","tumour and blood collection for realization ex vivo organoid models",[23],"Other: tumour and blood samples",[25],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":13},"tumour and blood samples","Tumour and blood samples",[20],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":13,"email":34},"Gwenn LE GALL, Medical Doctor","CONTACT","+33231455050","g.legall@baclesse.unicancer.fr",{"name":36,"role":32,"phone":37,"phoneExt":13,"email":38},"François CHERIFI, Medical Doctor","33231455050","f.cherifi@baclesse.unicancer.fr",[40],{"facility":41,"status":42,"city":43,"state":13,"zip":13,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Centre François Baclesse","RECRUITING","Caen","France","FR",{"type":47,"coordinates":48},"Point",[49,50],-0.35912,49.18585,{"lat":50,"lon":49},[53],{"name":31,"role":32,"phone":54,"phoneExt":13,"email":34},"332031455050",{"type":56,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100562464",false,"NCT06603506","Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study","PENDOR","Inclusion Criteria:\n\n* Patient aged 18 years or more\n* Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.\n* Patient with localized endometrial cancer, presenting:\n\n  * A high-grade endometrioid histological type and\u002For\n  * P53 mutation and\u002For\n  * a non-endometrioid histological type regardless of P53 status.\n* Patient affiliated to a social security scheme\n* Information and signature of informed consent prior to any specific study procedure\n\nExclusion Criteria:\n\n* Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).\n* Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.","FEMALE","18 Years",{"count":66,"type":67},16,"ESTIMATED","OBSERVATIONAL","This study comprises 3 stages:\n\n1. Collection of tumor and blood samples.\n2. Creation of organoid models based on tumor samples.\n3. Development of functional tests to predict clinical response to treatment.",[71],"Endometrial Cancer",[73,74,75],"endometrial cancer","organoide","PARP inhibitor","2024-11-25",{"date":78,"type":79},"2024-11-26","ACTUAL",{"date":81,"type":79},"2024-11-21",{"date":83,"type":67},"2027-10-15",{"name":5,"class":6},1]